Good afternoon. Thank you for joining us today to discuss Conversion Labs Third Quarter Results Ended September 30, 2020. Joining us today is the Chief Executive Officer of Conversion Labs, Justin Schreiber; and company’s Chief Financial Officer, Juan Piñeiro. Following their remarks, we will open the call to your question. Before we conclude today’s call, I will provide some important cautions regarding the forward-looking statements made by management during the call. I would like to remind everyone that today’s call is being recorded and will be made available for telecom replay via instructions in today’s press release, which is available in the Investor Relations section of the company’s website. Now I would like to turn the call over to Conversion Labs’ CEO, Justin Schreiber. Please go ahead, sir.

Thank you, Judy, and good afternoon, everyone. Thanks for joining us today. After the market closed, we reported another quarter of continued outperformance across our key financial and operational metrics. 2020 continues to be a transformational year for Conversion Labs. Most of the growth is due to the launch of our direct-to-consumer telemedicine platform and the overall performance of our entire brand portfolio generating strong organic growth and an increase in our subscription revenue. As we all know, the ongoing COVID-19 pandemic has accelerated everything e-commerce, for especially the adoption of telemedicine. This has greatly supported our aggressive growth strategy, focused on new patient acquisition and the continued optimization and build out of our technology platform. It’s important to emphasize the word platform. What you own as a shareholder in Conversion Labs is part of a direct-to-consumer telemedicine platform that is invalidated by our success this year in men’s health and hair loss. It has tremendous potential across the entire healthcare product world. The tailwinds created by this paradigm shift towards telehealth has clearly helped strengthen the demand for our brands, especially in the third quarter, resulting in record revenue of $11 million. This was up 21% from just the previous quarter, and up 252% compared to the same year ago quarter. This momentum has carried into the fourth quarter. As you may have seen, October was an outstanding month for us with net revenues of $4.1 million, which is greater than the revenue we generated in Q4 of last year. Looking at October and the first couple of weeks of November, we’ve achieved an overall annualized revenue run rate of nearly $50 million. This compares to $12.5 million for all of last year, a solid four-fold increase. This run rate is also up by more than $2.1 million from…

Thanks Juan. The momentum that we’ve seen throughout the year continued into the third quarter and continued into the final quarter with November on track to be our strongest month yet. Looking ahead, the telehealth opportunity for Conversion Labs is truly incredible. More importantly because of the increased access to healthcare enabled by telehealth companies like Conversion Labs, millions of Americans will gain access to important medical treatment that they otherwise might not have had access to. It’s very fulfilling for our whole team to be creating and delivering products and services that can make such a big difference in the lives of our customers and all the while creating tremendous value for our investors who have helped make this all happen. As an early mover in telehealth it’s paramount that we continue to make intelligent investments in our infrastructure to support our accelerating growth in this rapidly growing marketplace. This includes big investments in our telehealth technology platform, our provider networks and our medical, financial operations and compliance personnel that are critical as we scale the business. One of our biggest areas of focus in investment has been our internal customer service and sales team. In October, we leased space for a 400 seat call center in South Carolina and hired our first 40 customer representative. They’ve been doing phenomenal work, assisting our patients and customers over the last 60 days. And the positive feedback we’ve been receiving has been tremendous. I believe the goals and milestones we accomplished in the third quarter will prove to be invaluable going forward, setting a stronger foundation for more robust, even faster growth we’ve seen before. To support these investments in our growth, we recently completed a $15 million financing, led by a select group of institutional investors who believe in our…

Thank you. [Operator Instructions] With your first from Andrew DeSilva with B. Riley Securities.

Good afternoon. Thank you very much for taking my questions. Congrats on all the progress you’d make. I’m just hoping you could discuss stickiness of subscriptions and what kind of visibility that’s giving you right now? Also as it relates to the subscription, you noted all brands increased 30% quarter-over-quarter. Could you give a insight into how much of that growth is tied to cross-pollinization versus new Conversion Labs subscribers?

Sure. Thanks, Andy. Look, we haven’t formally put out retention numbers for our telemedicine business. So it’s tough to really say in a quantifiable way what the sickness is. But that’s a number that we plan to really start talking about, I think, in the first quarter, but we’ve seen – as we’ve communicated over and over to all of our shareholders, we’ve seen extremely strong unit economics with a relatively quick cash on cash return. Obviously, it’s a new business, so it’s a little bit – we have limited data on the kind of long-term lifetime value of these customers, but we’ll be talking more about that in 2021. I think that regarding to your second question, we don’t see at the moment a lot of cross-pollination between, for instance, Shapiro and Rex, and that’s more of an infrastructure thing. And one thing, Andy that we’re really going to start to see how – we think we’ll start to see how the call center and we already have a little bit is more of that happening. We’re investing a lot in training these reps to really help our patients. And also as we launched Veritas, that’s another interesting thing, right? As we bring on our – as we bring on – as we bring physicians onto our platform with the launch of Veritas, we’ll have more ability to – the physicians will have more of an ability to talk about the different products across our portfolio.

Useful color. Thank you. And the last question for me is just as far as demographics go; can you give a little sense of what the age of that total pool is right now? And where you’re finding the most success? Also just curious, how that others with some of the new offerings you’re expecting to add on in the coming quarters?

Sure. Yes, I’m going to let Stefan Galluppi answer that, who’s our Chief Marketing Officer. Stefan, do you want to talk a little bit about the demographics we’re seeing?

Yes, absolutely. For RexMD, the average age of our customers for the ED offer is 65 years old. So we’re a bit on the high side. And then what was the second question?

Yes. As far as the age demographic goes, how do you feel that bodes for you going forward as you begin to add on more offerings? Is that 65-year-old demographic ideal at this point? Or do you need to move down to younger age groups?

No. We think it fits perfectly in line with the rollout of all the additional categories that we’re entering into.

Okay. Perfect. Thank you very much. Best of luck closing out 2020.

Thanks, Andrew.

We’ll hear next from Corey Deutsch with Paradigm Opportunities, LLC.

Hey, Justin, Juan, and someone in the broader Conversion Labs team, first and foremost, I wanted to congratulate you guys on a truly phenomenal quarter.

Thanks, Corey.

Yes. And then second, obviously, this is not something that you guys are forecasting in our modeling, but with the recent upticks in COVID, and with the ongoing conversation about a potential second shutdown in the U.S.; how do you see the opportunity there in the sense of the expedited growth that may cause for the company?

Yes, that’s a great question. I think a lot of people – we’ve gotten some phone calls, right, with the Pfizer and Moderna vaccine announcements. And people tend to think that telemedicine is kind of a COVID play and that these vaccines are negative for the business. But, first of all, I disagree with that entirely, right, telemedicine is here to stay and COVID has accelerated this team and people are comfortable with that, it’s not going anywhere, it’s only going to grow. But, yes, as far as like – as far as the next couple of months ago, there’s without a doubt lockdowns drive e-commerce. So certainly like we saw early in the year with both our telemedicine portfolio and our over-the-counter and our SaaS portfolio like we – no question about it, Corey, that is if we see a lockdown – it will happen like we’re expecting over the winter months here, it’s a big growth driver for us. So how big, I’m not sure. And obviously, lockdown plus stimulus it’s an even bigger growth driver. So, but those two things although sad overall for the economy and for the population are our big growth drivers for Conversion Labs.

Yes. Thanks Justin. Again, congratulations on the quarter and regardless of what happens in the broader, how you guys are positioning the company for growth and winning going forward is very impressive. So great job guys.

Thank you. Juan Piñeiro: Thank you.

[Operator Instructions] Next from John DeMaio with Newbridge Securities.

Hey, you mentioned about the uplifting to the NASDAQ. You said one or two weeks, can you be a little bit more specific or you just don’t know?

We just don’t know, but we had a great – our council had a terrific call with the NASDAQ last week. We believe we’ve satisfied all of their requests. So we’re hopeful to get the green light any day, but they haven’t given us – they just haven’t given us the green light yet formally, there’s still just a couple of process that’s relatively quick. So we think it’s imminent.

Okay. Thank you.

At this time, I’d like to turn things back to Justin Schreiber for any closing remarks.

Thanks everyone for attending our call today. Thanks especially to our shareholders who have joined us during the most exciting time in our company’s history and everybody be well and stay happy. Julie, go ahead and wrap up the call.

Thank you ladies and gentlemen. Now before we conclude today’s call, I would like to provide the company’s safe harbor statements that include important cautions regarding forward-looking statements made during today’s call. The information that the company has provided in this conference call includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933. And section 21E of the Securities Exchange Act of 1934 as amended regarding among other things, the company’s plans, strategies and prospects both business and financial. Although the company believes that its plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, the company cannot assure you that it will achieve or realize these plans, intentions or expectations. Forward-looking statements are inherently subject to risks, uncertainties and assumptions. Many of the forward-looking statements made during this conference call maybe identified by the use of forward-looking words such as believe, expect, anticipate, should, plan, will, may, intend, estimated and potential, among others. Important factors that could cause actual results to differ materially from the forward-looking statements made during this conference call includes market conditions and those set forth in reports or documents that the company files from time-to-time with the United States Securities and Exchange Commission. All forward-looking statements attributable to Conversion Labs or a person acting on its behalf are expressly qualified entirely by this cautionary language. Before we end today’s conference call, I would like to remind everyone that this call will be available for replay starting later this evening and running through November 30. Please refer to today’s earnings release for dial-in replay instructions available via the company’s website at www.conversionlabs.com. Thank you for joining us today. This concludes today’s conference call. You may now disconnect.